CytomX Therapeutics, Inc. (CTMX)

2,0400 -2,1500 (-51,31%) Börsenschluss: 04:00PM EDT

CytomX Therapeutics, Inc.

151 Oyster Point Boulevard
Suite 400
South San Francisco, CA 94080
United States
650 515 3185
https://www.cytomx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 120

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Sean A. McCarthy DPHIL	Chairman & CEO	1,03M	N/A	1967
Dr. Marcia P. Belvin Ph.D.	Senior VP & Chief Scientific Officer	634,83k	N/A	N/A
Mr. Jeffrey Landau B.S., M.B.A.	Senior VP, Head of Strategy & Chief Business Officer	580,69k	N/A	1979
Mr. Christopher W. Ogden	Senior VP of Finance & Accounting	N/A	N/A	1984
Mr. Lloyd A. Rowland Jr., J.D.	Senior VP, General Counsel, Chief Compliance Officer & Secretary	608,72k	N/A	1957
Ms. Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer	N/A	N/A	N/A
Ms. Leslie Robbins	Senior Vice President of Intellectual Property	N/A	N/A	N/A
Dr. Yu-Waye Chu M.D.	Chief Medical Officer	N/A	N/A	1968
Ms. Dawn Benson	Senior Vice President of Quality & Product Manufacturing	N/A	N/A	N/A
Dr. Hoyoung Huh M.D., Ph.D.	Special Advisor to Chief Executive Officer	72,5k	N/A	1969

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Corporate Governance

CytomX Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 6, Vorstand: 8, Shareholderrechte: 3, Kompensation: 8.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.